CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 29 enrolled
Drug / intervention
Radium-223drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02278055
NCT02278055Phase 2Completed
CompareCT.gov

Phase II Open, Non-Randomized Trial Assessing Pain Efficacy With Radium-223 in Symptomatic Metastatic Castration-Resistant Prostate Cancer

Memorial Sloan Kettering Cancer Center·interventional·Posted Oct 29, 2014·Updated Apr 7, 2023

In Brief

A Phase 2 clinical trial evaluating Radium-223 for Metastatic Prostate Cancer and Pain. Completed, enrolled 29 participants across 3 sites.

Detailed Summary

The purpose of this study is to find out if Radium-223 is effective in reducing cancer pain within 12 weeks of treatment. In order to see if Radium-223 is effective, the patient's level of pain will be followed throughout the study.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetastatic Prostate Cancer, Pain
CountriesUnited States
CollaboratorsUniversity of North Carolina, New York Presbyterian Hospital

Timeline

Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedOct 29, 2014
Enrollment StartOct 8, 2014
Primary CompletionFeb 2, 2022
TodayJul 2, 2026
Enrollment to primary: 7.3 yearsPosted 11.7 years ago

Interventions

Radium-223drug